Wegovy price India: Danish drugmaker Novo Nordisk has reduced the list price of its obesity drug Wegovy in India by as much as 37% from launch, seeking an edge in one of the fastest-growing markets for weight-loss treatments.
A company notice to distributors shows the monthly pack of the highest 2.4 mg dose will now cost ₹16,400 ($186.6), down from ₹24,389.06, while the starter 0.25 mg dose falls to ₹10,850 from ₹16,260.94.
Also Read | US adult obesity rate dips as weight-loss drug use surges, survey finds
The cuts reflect both a company move and the impact of a September revision to India’s sales tax structure that made the drug slightly cheaper. “We have made sure to listen to our patient and doctor communities,” said Vikrant Shrotriya, managing director, Novo Nordisk India.
Wegovy, which launched in India in June, is competing with Eli Lilly’s Mounjaro, introduced in March and now India’s top-selling drug by value in October. Both medicines are GLP-1 receptor agonists used in obesity and diabetes care.
Analysts say Wegovy’s price move could help Novo Nordisk defend its share ahead of expected generic competition when semaglutide’s Indian patent expires in March 2026. “This might be a move to be able to sell more,” said Vishal Manchanda of Systematix Institutional Equities, noting Mounjaro is “doing better” in the market.
To broaden reach, Lilly has partnered with Cipla to distribute Mounjaro, while Novo Nordisk has tied up with Emcure Pharma for Wegovy. Earlier this month in the US, Lilly and Novo agreed to lower prices for their weight-loss drugs for Medicare, Medicaid and cash-paying patients.